Clinical Trials

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients with Select Solid Tumors (FRONTIER)

Link : https://clinicaltrials.gov/ct2/show/NCT05432193?term=NCT05432193&draw=2&rank=1
Status : PENDING
Population : High grade soft tissue sarcoma
Description : FAPi radioligand in high grade soft tissue sarcoma
PI : A. Razak
Centers Opened : Princess Margaret Cancer Centre
Phase : I
IIST/Pharma : Pharma